ABSTRACT
Introduction: Transplacental infections are frequent, especially in developing countries, where limited screening is performed to find infectious agents in the pregnant population. We aim to determine the clinical and epidemiological characteristics and seroinfection of antibodies against Toxoplasma, parvovirus B19, T. pallidum, and HIV in pregnant women who attended the Motupe Health Center in Lambayeque, Peru during July-August 2018. Methods: A descriptive cross-sectional study was conducted in 179 pregnant women interviewed with a standardized questionnaire. ELISA was used to determine antibodies to Toxoplasma and parvovirus B19. The detection of syphilis and HIV was conducted using immunochromatography, while the detection of hepatitis B was conducted using FTA-ABS and immunofluorescence, respectively. Results: Of 179 pregnant women, syphilis and HIV infections routinely included in the screening of pregnant women presented a seroinfection of 2.2 and 0.6%, respectively. Toxoplasmosis seroinfection was 25.1%, while IgM antiparvovirus B19 was 40.8%, revealing that pregnant women had an active infection at the time of study. Conclusion: The level of seroinfection of toxoplasmosis reveals the risk to which pregnant women who participated in the study are exposed. The high seroinfection of parvovirus B19 could explain the cases of spontaneous abortion and levels of anemia in newborn that have been reported in Motupe, Lambayeque, Peru. However, future causality studies are necessary to determine the significance of these findings.
Subject(s)
HIV Infections , Parvovirus B19, Human , Pregnancy Complications, Infectious , Syphilis , Toxoplasma , Toxoplasmosis , Treponema pallidum , Humans , Female , Pregnancy , Peru/epidemiology , Treponema pallidum/immunology , Adult , Cross-Sectional Studies , Syphilis/epidemiology , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/virology , Toxoplasmosis/epidemiology , Toxoplasmosis/immunology , HIV Infections/epidemiology , Toxoplasma/immunology , Young Adult , Parvovirus B19, Human/immunology , Antibodies, Protozoan/blood , Antibodies, Viral/blood , Adolescent , Seroepidemiologic StudiesABSTRACT
BACKGROUND: The immature and suppressed immune response makes transplanted children a special susceptible group to Parvovirus B19 (PVB19). However, the clinical features of transplanted children with PVB19 infection haven't been comprehensively described. METHODS: We searched the medical records of all the transplant recipients who attended the Children's Hospital of Fudan University from 1 Oct 2020 to 31 May 2023, and reviewed the medical literature for PVB19 infection cases among transplanted children. RESULTS: A total of 10 cases of PVB19 infection were identified in 201 transplanted children at our hospital, and the medical records of each of these cases were shown. Also, we retrieved 40 cases of PVB19 infection among transplanted children from the literature, thus summarizing a total of 50 unique cases of PVB19 infection. The median time to the first positive PVB19 DNA detection was 14 weeks post-transplantation. PVB19 IgM and IgG were detected in merely 26% and 24% of the children, respectively. The incidence of graft loss/dysfunction was as high as 36%. Hematopoietic stem cell transplant (HSCT) recipients showed higher PVB19 load, lower HGB level, greater platelet damage, lower PVB19 IgM/IgG positive rates, and more graft dysfunction than solid-organ transplant (SOT) recipients, indicating a more incompetent immune system. CONCLUSIONS: Compared with the published data of transplanted adults, transplanted children displayed distinct clinical features upon PVB19 infection, including lower PVB19 IgM/IgG positive rates, more graft dysfunction, and broader damage on hematopoietic cell lines, which was even more prominent in HSCT recipients, thus should be of greater concern.
Subject(s)
Antibodies, Viral , Hematopoietic Stem Cell Transplantation , Parvoviridae Infections , Parvovirus B19, Human , Humans , Parvovirus B19, Human/immunology , Parvovirus B19, Human/genetics , Child , Female , Male , Child, Preschool , Parvoviridae Infections/virology , Parvoviridae Infections/immunology , Hematopoietic Stem Cell Transplantation/adverse effects , Antibodies, Viral/blood , Infant , Adolescent , Immunoglobulin M/blood , Immunoglobulin G/blood , Transplant Recipients , DNA, Viral/blood , Viral Load , Organ Transplantation/adverse effectsABSTRACT
BACKGROUND: Parvovirus B19(B19) is a DNA virus. The most common B19 disease is erythema infectiosum (fifth-disease). PCR and ELISA are sensitive for detecting of acute disease. However, it is not clear which test better and the relationship between laboratory tests and clinical findings. OBJECTIVE: To discuss the clinical and laboratory characteristics of pediatric patients infected with B19. STUDY DESIGN: 236 children were examined. Children with at least one positive molecular or serological test were included. Positive serum B19-DNA and/or B19-IgM was considered an acute B19 infection. RESULTS: B19DNA was detected in 80.8 % of acute cases. Serological tests were less positive. Acute B19 infection was observed in 24 patients. Only 17 patients were positive for B19 DNA, 3 for IgM and 4 for both. The sensitivity of B19 DNA is 87.5 %. However, this rate is 29.2 % for B19 IgM. CONCLUSION: B19-DNA and IgM together provide a better, highly accurate diagnosis.
Subject(s)
Antibodies, Viral , DNA, Viral , Erythema Infectiosum , Immunoglobulin M , Parvovirus B19, Human , Humans , Parvovirus B19, Human/genetics , Parvovirus B19, Human/immunology , Parvovirus B19, Human/isolation & purification , Child , Immunoglobulin M/blood , Child, Preschool , Female , Male , DNA, Viral/blood , Antibodies, Viral/blood , Erythema Infectiosum/diagnosis , Erythema Infectiosum/blood , Erythema Infectiosum/immunology , Infant , Sensitivity and Specificity , Adolescent , Polymerase Chain Reaction/methods , Parvoviridae Infections/diagnosis , Parvoviridae Infections/blood , Parvoviridae Infections/immunology , Parvoviridae Infections/virology , Enzyme-Linked Immunosorbent Assay , Serologic Tests/methodsABSTRACT
This is a case report of a 6-year-old girl with relapsed B cell acute lymphoblastic leukemia in which adoptive cell therapy was applied successfully to treat refractory human parvovirus (HPV) B19 infection. Allogenic chimeric antigen receptor (CAR) T-cell therapy (bispecific CD19/CD22) was bridged to hematopoietic stem cell transplantation (HSCT) using a haploidentical paternal donor. However, HPV B19 DNAemia progressed and transfusion-related graft versus host disease occurred. After finding a third-party related donor with a better HLA match, haploidentical HPV B19-seropositive CD45RA+ depleted cells (16.5 × 106/kg) were administered and paternal TCRαß+ depleted stem cell were retransplanted. The HPV B19 DNAemia became negative within 1 week and the reticulocyte, neutrophil, hemoglobin, and platelet counts gradually normalized. The patient remained stable during the 1-year outpatient follow-up period. Thus, our case report highlights that persistent B19 infection can lead to pancytopenia, aplastic crisis, and graft rejection and TCRαß+ depleted haplo-HSCT is an effective means of hematopoiesis recovery. CD45RO memory T-cell therapy is the key to treating and preventing the development of refractory severe HPV B19 infection.
Subject(s)
Hematopoietic Stem Cell Transplantation , Parvoviridae Infections , Parvovirus B19, Human , Receptors, Antigen, T-Cell, alpha-beta , Humans , Female , Child , Parvovirus B19, Human/immunology , Parvoviridae Infections/therapy , Parvoviridae Infections/immunology , Leukocyte Common Antigens/metabolism , Immunotherapy, Adoptive/methods , Anemia, Aplastic/therapy , Anemia, Aplastic/immunology , Graft vs Host Disease/therapy , Graft vs Host Disease/immunology , Treatment Outcome , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/immunologyABSTRACT
BACKGROUND: There should be a heightened index of suspicion for Parvovirus B19 (PVB19)-related anemia in organ transplant recipients. Thus far, there is no consensus or recommendation for clinical routine monitoring methods of PVB19 recipients to allow tailoring of immunosuppression. METHODS: We conducted a retrospective study to evaluate the utility of the function (represented by the abilities to secrete IFN-γ) and numbers of lymphocyte subsets in monitoring PVB19 infections in renal recipients posttransplant. The enrolled 109 patients were split into 2 groups according to whether the recipients had an occurrence of PVB19 infection: 37 (33.94%) recipients developed PVB19 infection and 72 (66.06%) immune-stable recipients. RESULTS: The PVB19 infected group had significantly lower absolute counts and functions of different lymphocyte subsets compared with immune-stable recipients. We showed that the frequencies of IFN-γ + CD4 + T cells, IFN-γ + CD8 + T cells, and IFN-γ + NK cells increased markedly after treatment when compared to the occurrence in patients with timepoint before therapy, especially the percentages of IFN-γ + CD4 + T cells were significantly higher. Receiver operating characteristic (ROC) analysis showed that the optimal infection indicator was IFN-γ + NK cells frequency, with an auROC curve of 0.925. Concomitantly, Cox regression analysis indicated that the post-therapy increasing level of IFN-γ secreting function was significantly predictive of recurrent infections (P < 0.001). CONCLUSIONS: We recommend prospective risk stratification for the high-risk population at risk of early-onset PVB19 infection and its recurrence involves screening strategies of immune-based surveillance with the sensitive IFN-γ + secreting monitoring for antiviral prophylaxis and preemptive therapy goal. Clinical Trial Notation: clinical trial registration number: chiCTR-ROC-17010756.
Subject(s)
Erythema Infectiosum , Interferon-gamma , Kidney Transplantation , Parvovirus B19, Human , Erythema Infectiosum/immunology , Humans , Interferon-gamma/analysis , Kidney Transplantation/adverse effects , Lymphocyte Subsets/immunology , Parvovirus B19, Human/immunology , Retrospective Studies , Transplant RecipientsABSTRACT
Background: Human parvovirus B19 (B19) can cause acute hepatitis and is attributed to the high mortality of alcoholic hepatitis (AH). B19 infection is generally self-healing in previously healthy people, but it can cause fatal effects in some high-risk groups and increase its virulence and infectivity. Disseminated B19 infection-induced multiple organ dysfunction syndrome (MODS) in patients with AH has not been reported yet. Here, we described B19 viremia in an adult patient with AH accompanied by hemolytic anemia (HA), leading to disseminated infection and secondary MODS, as well as self-limiting B19 infections in seven nurses caring for him. Meanwhile, we reviewed the literature on AH and B19 infection. Case Presentation: A 43-year-old male patient with AH accompanied by HA was transferred to the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, on March 31, 2021. After supportive treatment, his transaminase and bilirubin levels were reduced, but his anemia worsened. He received a red blood cell (RBC) infusion on April 9 for hemoglobin (Hb) lower than 6 g/dl. On April 13, he suddenly had a high fever. Under empirical anti-infection, his high fever dropped and maintained at a low fever level; however, his anemia worsened. On April 25, he was transferred to the medical intensive care unit (MICU) due to severe pneumonia, acute respiratory distress syndrome (ARDS), acute aplastic crisis (AAC), and hemophagocytic syndrome (HPS), which were subsequently confirmed to be related to B19 infection. After methylprednisolone, intravenous immunoglobulin (IVIG), empirical anti-infection, and supportive treatment, the lung infection improved, but hematopoietic and liver abnormalities aggravated, and systemic B19 infection occurred. Finally, the patient developed a refractory arrhythmia, heart failure, and shock and was referred to a local hospital by his family on May 8, 2021. Unfortunately, he died the next day. Fourteen days after he was transferred to MICU, seven nurses caring for him in his first two days in the MICU developed self-limiting erythema infectiosum (EI). Conclusions: B19 infection is self-limiting in healthy people, with low virulence and infectivity; however, in AH patients with HA, it can lead to fatal consequences and high contagion.
Subject(s)
Anemia, Hemolytic/immunology , Hepatitis, Alcoholic/immunology , Multiple Organ Failure/immunology , Parvoviridae Infections/immunology , Parvovirus B19, Human/immunology , Adult , Hepatitis, Alcoholic/diagnosis , Humans , Male , Multiple Organ Failure/diagnosis , Parvoviridae Infections/diagnosisABSTRACT
Infection of the heart muscle with cardiotropic viruses is one of the major aetiologies of myocarditis and acute and chronic inflammatory cardiomyopathy (DCMi). However, viral myocarditis and subsequent dilated cardiomyopathy is still a challenging disease to diagnose and to treat and is therefore a significant public health issue globally. Advances in clinical examination and thorough molecular genetic analysis of intramyocardial viruses and their activation status have incrementally improved our understanding of molecular pathogenesis and pathophysiology of viral infections of the heart muscle. To date, several cardiotropic viruses have been implicated as causes of myocarditis and DCMi. These include, among others, classical cardiotropic enteroviruses (Coxsackieviruses B), the most commonly detected parvovirus B19, and human herpes virus 6. A newcomer is the respiratory virus that has triggered the worst pandemic in a century, SARS-CoV-2, whose involvement and impact in viral cardiovascular disease is under scrutiny. Despite extensive research into the pathomechanisms of viral infections of the cardiovascular system, our knowledge regarding their treatment and management is still incomplete. Accordingly, in this review, we aim to explore and summarize the current knowledge and available evidence on viral infections of the heart. We focus on diagnostics, clinical relevance and cardiovascular consequences, pathophysiology, and current and novel treatment strategies.
Subject(s)
COVID-19/virology , Cardiomyopathy, Dilated/virology , Myocarditis/virology , Parvoviridae Infections/virology , Parvovirus B19, Human/pathogenicity , SARS-CoV-2/pathogenicity , Animals , Antiviral Agents/therapeutic use , COVID-19/diagnosis , COVID-19/immunology , COVID-19/therapy , Cardiomyopathy, Dilated/diagnosis , Cardiomyopathy, Dilated/immunology , Cardiomyopathy, Dilated/therapy , Genetic Therapy , Host-Pathogen Interactions , Humans , Myocarditis/diagnosis , Myocarditis/immunology , Myocarditis/therapy , Parvoviridae Infections/diagnosis , Parvoviridae Infections/immunology , Parvoviridae Infections/therapy , Parvovirus B19, Human/immunology , SARS-CoV-2/immunology , COVID-19 Drug TreatmentABSTRACT
A unique region of human parvovirus B19 virusVP1 (B19VVP1u) has been linked to a variety of cardiac disorders. However, the precise role of B19VVP1u in inducing cardiac injury remains unknown. The present study investigated the effects of B19VVP1u and different regions of B19VVP1u, including B19VVP1uA (residues 160), B19VVP1uB (residues 61129), B19VVP1uC (residues 130195) and B19VVP1uD (residues 196227), on inducing cardiac injury in naïve mice by zymography, immunoblotting, H&E staining and cytokine immunoassay. A significantly higher MMP9/MMP2 ratio and increased levels of inflammatory cytokines, including IL6 and IL1ß, were detected in the left ventricles of the mice injected with B19Vnonstructural protein 1 (B19VNS1) and B19VVP1u, accompanied by increased expression levels of phosphorylated (p)ERK and pP38. Significantly upregulated expression levels of atrial natriuretic peptide (ANP), hearttype fatty acidbinding protein (HFABP) and creatine kinase isoenzymeMB (CKMB), which are wellknown cardiac injury markers, as well as increased infiltration of lymphocytes, were detected in the left ventricles of the mice injected with B19VVP1, B19VNS1 and B19VVP1u. Moreover, a significantly higher MMP9/MMP2 ratio and increased levels of IL6 and IL1ß were observed in the left ventricles of the mice injected with B19VVP1u, B19VVP1uA, B19VVP1uB and B19VVP1uC, accompanied by upregulated pERK and pP38 expression. Notably, significantly lower levels of IL6 and IL1ß were observed in the left ventricles of the mice injected with B19VVP1uD. Furthermore, significantly increased ANP, HFABP and CKMB expression levels were detected in the left ventricles of the mice injected with B19VVP1u, B19VVP1uA and B19VVP1uB, along with enhanced infiltration of lymphocytes. Significantly higher serum IL1ß, IL6, TNFα and IFNγ levels were also detected in the mice injected with B19VVP1u, B19VVP1uA and B19VVP1uB. To the best of our knowledge, the findings of the present study were the first to demonstrate that the Nterminal region (residues 1129) of B19VVP1u induces an increase in the levels of cardiac injury markers, thus providing evidence for understanding the possible functional regions within B19VVP1u.
Subject(s)
Capsid Proteins/immunology , Heart Injuries/immunology , Parvoviridae Infections/complications , Parvovirus B19, Human/immunology , Animals , Capsid Proteins/genetics , Capsid Proteins/isolation & purification , Cytokines/blood , Cytokines/metabolism , Disease Models, Animal , Female , Heart Injuries/blood , Heart Injuries/pathology , Heart Injuries/virology , Host-Pathogen Interactions/immunology , Humans , Mice , Parvoviridae Infections/blood , Parvoviridae Infections/immunology , Parvoviridae Infections/virology , Parvovirus B19, Human/genetics , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/isolation & purification , Signal Transduction/immunologyABSTRACT
Cancer immunotherapy is emerging as a viable treatment option for several types of cancer. Active immunotherapy aims for the induction of specific antitumor immune responses; this goal requires strategies capable of increasing the immunogenicity of tumour antigens. Parvovirus B19 virus-like particles (B19-VLPs) formed of VP2 protein had been shown to be an effective multi-neoepitope delivery system capable of inducing specific cellular responses towards coupled antigens and reducing tumour growth and lung metastases in triple negative breast cancer mouse model. These findings encouraged us to further characterise these VP2 B19-VLPs by testing their capacity to simultaneously induce cellular and humoral responses towards other tumour-associated antigens, as this had not yet been evaluated. Here, we designed and evaluated in the 4T1 breast cancer model the prophylactic and therapeutic effect of VP2 B19-VLPs decorated with cellular (P53) and humoral (MUC1) epitopes. Balb/c mice were immunised with chimaeric VLPs, vehicle, or VLPs plus adjuvant. Tumour establishment and growth, lung metastasis, and cellular and humoral immune responses were evaluated. The prophylactic administration of chimaeric VLPs without adjuvant prevented the establishment of the tumour, while by therapeutic administration, chimaeric VLPs induced smaller tumour growth and decreased the number of metastases in the lung compared to wild-type VLPs. chimaeric VLPs induced high antibody titres towards the MUC1 epitope, as well as specific cellular responses towards P53 epitopes in lymph nodes local to the tumour. Our results reinforce and extend the utility of VP2 B19-VLPs as an encouraging tumour antigen delivery system in cancer immunotherapy able to improve tumour immunity in TNBC by inducing cellular and humoral immune responses.
Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Parvovirus B19, Human/immunology , Triple Negative Breast Neoplasms/therapy , Vaccines, Virus-Like Particle/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Antigens, Neoplasm/administration & dosage , Bacillus thuringiensis Toxins/administration & dosage , Cancer Vaccines/administration & dosage , Cell Line, Tumor , Disease Models, Animal , Endotoxins/administration & dosage , Female , Hemolysin Proteins/administration & dosage , Humans , Immunity, Cellular , Immunity, Humoral , Immunogenicity, Vaccine , Insect Proteins , Mice , Receptors, Cell Surface , Triple Negative Breast Neoplasms/immunology , Triple Negative Breast Neoplasms/pathology , Vaccines, Virus-Like Particle/administration & dosageABSTRACT
BACKGROUND: Parvovirus B19 is a pathogenic virus often diagnosed by serology, yet little is known about analytical performance of commercial enzyme immunoassays (EIAs). OBJECTIVE: To investigate performance of 4 EIAs for parvovirus B19 IgM and IgG: Liaison, Euroimmun, Mikrogen and Virion/Serion. STUDY DESIGN: To compare 4 EIAs to Biotrin's ELISA on 168 samples and determine consensus score for discordant samples using Mikrogen's confirmatory line assay. RESULTS: Two thirds of results for IgM/IgG were identical for all 4 EIAs and Biotrin. Liaison shows the highest IgM sensitivity, but has low specificity. Euroimmun lacks IgM sensitivity. Mikrogen had a good overall performance, but had the lowest IgG specificity. Virion/Serion had variable performance with a low IgM specificity and the most borderline and cross-reactive results. CONCLUSIONS: Liaison and Mikrogen have similar performance to Biotrin's ELISA. Euroimmun lacks sensitivity and Virion/Serion produced many borderline and cross-reactive results.
Subject(s)
Antibodies, Viral/blood , Erythema Infectiosum/diagnosis , Immunoenzyme Techniques/standards , Parvovirus B19, Human/immunology , Serologic Tests/standards , Erythema Infectiosum/immunology , Humans , Immunoenzyme Techniques/methods , Immunoglobulin G/blood , Immunoglobulin M/blood , Sensitivity and Specificity , Serologic Tests/methodsABSTRACT
BACKGROUND: In the Iraqi community, abnormal pregnancy forms a major social and psychological health problem. The underlying etiology of this health phenomenon was varied and included sets of infections and autoimmune diseases. Globally human parvovirus 19 infection is common and the infection attributes to bad obstetric outcomes. The global maternal parvovirus B19 remote infection rate was within a range of 13.2% to 97.9%, while the range of acute infection was between 0.5% to 97.9%. In Arab countries, the IgG seroprevalence was from 53.3% to 74%, while IgM seroprevalence range was 2.2% to 84%. OBJECTIVE: To evaluate the role of ParvovirusB19 as an etiology of bad obstetric outcome in women in Kirkuk, Iraq. MATERIALS AND METHODS: Descriptive Case Control Study. Women included in the study were recruited from Kirkuk General Hospital and their age ranged from 14 to 48 years. A total of 663 women were included in the study, of them 237 were not pregnant, while 215 were pregnant. Additionally, the study included 211 women with inevitable abortion. Control group (306 women) women with a history of normal pregnancy included (Pregnant= 149; non-pregnant= 157). Clinical and laboratory investigations were conducted on all patients and control groups to exclude other causes. Medical and obstetric data and demographic characteristics were gathered through interviews according to a previously designed questionnaire. ELISA kits were used to determine Parvovirus B19 IgM and IgG antibodies. RESULTS: The overall parvovirus seroprevalence was 93% and with no significant difference between women with normal (89.5%) and those with abnormal (93.1%) pregnancy outcomes. In addition, parvovirus IgM overall seroprevalence was at56.3%. Furthermore, current parvovirus infection was higher in women with BOH (52.6%) than that in women with normal pregnancy (49.7%) outcomes. Parvovirus IgM seroprevalence was 52.6% in women with BOH and 49.7% in women with normal pregnancy, however, the difference was not statistically significant. In contrast, the acute infection with parvovirus was significantly (X2=11.8, P=0.001) lower in women with normal pregnancy (49.7%) than in those with inevitable abortion (64.9%). While the IgG seroprevalence difference was not significant between the two groups, infection seroprevalence was more frequent in housewives, uneducated women, large families, non-smokers, in rural areas, non-animal exposure areas, women with repeated abortion, congenital anomalies and anaemia. CONCLUSION: Parvovirus B19 infection may be with bad obstetric outcomes if occurred during pregnancy and OR confirmed a significant association of the infection with parvovirus with smoking, occupation, crowding index, education, animal exposure and the number of repeated abortion.
Subject(s)
Abortion, Spontaneous/virology , Antibodies, Viral/blood , Parvoviridae Infections/epidemiology , Parvovirus B19, Human/isolation & purification , Pregnancy Complications, Infectious/diagnosis , Abortion, Spontaneous/epidemiology , Adolescent , Adult , Case-Control Studies , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Iraq/epidemiology , Middle Aged , Parvoviridae Infections/immunology , Parvovirus B19, Human/immunology , Pregnancy , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/virology , Pregnancy Outcome , Pregnant Women , Seroepidemiologic Studies , Young AdultABSTRACT
BACKGROUND: Human parvovirus B19V is a DNA virus, and a member of the family Parvoviridae, that causes various clinical manifestations, from asymptomatic to persistent infection that is associated with different autoimmune diseases. The parvovirus B19 evolves with a very high mutation rate that is closer to those of existing RNA viruses. Globally circulating B19V is currently classified into three genotypes, but their distribution is not spatially and temporally correlated. Except for a few recent reports on B19V entry into the human host and its genetic diversity, there is a lack of sufficient studies on this virus from distinct geographical locations and no clear understanding of its evolution has been documented. METHODS: To better understand the evolution of the Human parvo B19V virus from India's southern part, a geographically distinct location with no reports of B19V genomes, we have screened for B19V in 456 suspected cases using VP1/2 surface marker genes, and its characteristics were studied in detail. Amongst 456 clinically suspected B19V samples, 7.2% (33/456) were found positive by nested PCR (nPCR) were subsequently validated by real-time PCR, Sanger sequencing, and metagenome analysis. RESULTS: Human parvovirus B19 infection was shown among 33 of 456 patients when tested by nPCR; 30 among these were also positive by qPCR and were subsequently confirmed by sequencing 75% nPCR positive samples and 76% qPCR positive samples were from patients with age. ≥ 50 years respectively (Additional file 1: Table S1). The complete VP1/2 gene assembly from the South Indian strain showed three novel mutations (T122A, V128I, I283V), which might significantly impact the stability and virulence of the B19V virus circulating in this part of the world. These mutations might be crucial for its adaptive evolutionary strategies facilitating the spread and infectivity potential of the virus. In maximum likelihood phylogeny of VP1/2 sequences, the South Indian B19V strain forms a separate clade closer to the existing genotype two strains circulating worldwide. CONCLUSION: Our study contributes to a better understanding of the human parvovirus's genetic and evolutionary characteristics in South India. Also, it highlights the possibility that a positive selection pressure acting on VP1/2 could increase the survival and replication capabilities of the viruses.
Subject(s)
Parvoviridae Infections , Parvovirus B19, Human , Antibodies, Viral , DNA, Viral/genetics , Humans , India/epidemiology , Parvoviridae Infections/epidemiology , Parvovirus B19, Human/genetics , Parvovirus B19, Human/immunology , Persistent Infection , Real-Time Polymerase Chain ReactionABSTRACT
A causal link between viral infections and autoimmunity has been studied for a long time and the role of some viruses in the induction or exacerbation of systemic lupus erythematosus (SLE) in genetically predisposed patients has been proved. The strength of the association between different viral agents and SLE is variable. Epstein-Barr virus (EBV), parvovirus B19 (B19V), and human endogenous retroviruses (HERVs) are involved in SLE pathogenesis, whereas other viruses such as Cytomegalovirus (CMV) probably play a less prominent role. However, the mechanisms of viral-host interactions and the impact of viruses on disease course have yet to be elucidated. In addition to classical mechanisms of viral-triggered autoimmunity, such as molecular mimicry and epitope spreading, there has been a growing appreciation of the role of direct activation of innate response by viral nucleic acids and epigenetic modulation of interferon-related immune response. The latter is especially important for HERVs, which may represent the molecular link between environmental triggers and critical immune genes. Virus-specific proteins modulating interaction with the host immune system have been characterized especially for Epstein-Barr virus and explain immune evasion, persistent infection and self-reactive B-cell "immortalization". Knowledge has also been expanding on key viral proteins of B19-V and CMV and their possible association with specific phenotypes such as antiphospholipid syndrome. This progress may pave the way to new therapeutic perspectives, including the use of known or new antiviral drugs, postviral immune response modulation and innate immunity inhibition. We herein describe the state-of-the-art knowledge on the role of viral infections in SLE, with a focus on their mechanisms of action and potential therapeutic targets.
Subject(s)
Cytomegalovirus/immunology , Endogenous Retroviruses/immunology , Herpesvirus 4, Human/immunology , Immunity, Innate/immunology , Lupus Erythematosus, Systemic/immunology , Parvovirus B19, Human/immunology , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/virology , Autoimmunity/immunology , Cytomegalovirus Infections/pathology , Endogenous Retroviruses/physiology , Epstein-Barr Virus Infections/pathology , Herpesvirus 4, Human/physiology , Host-Pathogen Interactions/physiology , Humans , Lupus Erythematosus, Systemic/virology , Parvoviridae Infections/pathology , Parvovirus B19, Human/physiologyABSTRACT
Human Parvovirus B19 (B19 V) infection is hyperendemic in Nigeria. Pregnant women are not classically immunocompromised but maybe physiologically immunosuppressed and susceptible to viral infection. However, there is a paucity of studies on the epidemiology of B19V in Jigawa State, Northwestern Nigeria. This study aims to determine the seroprevalence, sociodemographic, and risk factors of human B19V infection among present women attending antenatal clinics of Jahun General Hospital, Nigeria. Between 2 February and 30 June 2019, blood samples were collected from 200 consented pregnant women and analyzed for anti-B19V IgM and IgG using commercially available enzyme-linked immunosorbent assay (ELISA). Sociodemographic and risk factors of subjects were collated through pre-tested structured questionnaires. Data generated were statistically analyzed for the association of anti-B19V and subjects' variables studied. Overall, the seroprevalence of anti-B19V IgM and IgG among pregnant women attending antenatal clinics of Jahun General Hospital, Nigeria was 6.0% and 22.5%, respectively. There was no significant association between the seroprevalence of anti-B19V IgM and anti-B19V IgG with all the sociodemographic variables and risk factors of pregnant women (P Ë0.05). However, pregnant women with a history of blood transfusion had a significant risk associated with seroprevalence of B19V IgM (OR = 5.95; 95% CI: 1.96-22.76; P = .009). Findings from this study revealed that a high proportion of the pregnant women were susceptible to B19V infection and anti-B19V IgG immunity decreased with age. Given the incidence of acute B19V infection, it is clinically important to continuously monitor their erythrocytes indices and screen their neonates for B19V infection and fetal complications.
Subject(s)
Parvoviridae Infections/diagnosis , Parvovirus B19, Human/immunology , Adolescent , Adult , Cross-Sectional Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Nigeria/epidemiology , Parvoviridae Infections/immunology , Pregnancy , Risk Factors , Young AdultABSTRACT
Human parvovirus B19 (B19V) infection is not notifiable in Belarus and its most common clinical presentation erythema infectiosum (EI) is often difficult to distinguish from other exanthematous diseases. The objective of this study was to provide comprehensive data about EI epidemiology in Belarus based on the serological and molecular investigation of samples from measles and rubella discarded cases collected between 2005 and 2019. Overall, 4919 sera were investigated for IgM antibodies against B19V and the positive cases were analysed according to year, season and age. B19V DNA was amplified by PCR in a total of 238 sera from all over the country, and sequenced for phylogenetic analyses. B19V infection was confirmed in 1377 (27.8%) measles and rubella discarded cases. Two high incidence periods and a seasonal increase of EI between mid-February to mid-July were identified. Children from 4 to 6 and from 7 to 10 years of age represented the largest groups of patients (22.51% and 22.66% of all cases, respectively), followed by adults between 20 and 29 years of age (14.23%). Among the 238 B19Vs sequenced, one belonged to subgenotype 3b and 237 to subgenotype 1a with 81 (34.2%) clustering with subtypes 1a1 and 153 (64.6%) with 1a2. Three strains (1.2%) formed an additional, well-supported cluster suggesting the presence of another subtype of 1a, tentatively named 1a3. The epidemiological and molecular analyses highlighted not only the prominent role of B19V in exanthematous diseases in Belarus, but also suggested a previously underestimated diversity of subgenotype 1a sequences with a third subtype 1a3.
Subject(s)
Parvoviridae Infections/virology , Parvovirus B19, Human/genetics , Adolescent , Adult , Antibodies, Viral/immunology , Child , Child, Preschool , DNA, Viral/genetics , Female , Genotype , Humans , Immunoglobulin M/immunology , Infant , Male , Middle Aged , Parvoviridae Infections/immunology , Parvovirus B19, Human/immunology , Phylogeny , Republic of Belarus , Sequence Analysis, DNA/methods , Young AdultABSTRACT
Congenital parvovirus B19 infection is a rare but serious condition that can result in hydrops fetalis and fetal death. Due to the virus' cytotoxic effect on fetal red blood cell precursors, postnatal infection can cause a neonatal viremia and secondary pure red cell aplasia. Here, we describe a case of congenital parvovirus infection in a preterm infant complicated by hydrops fetalis and chronic anaemia that responded to postnatal treatment with intravenous immunoglobulin administered on day of life 44. After treatment, the anaemia resolved as the neonate exhibited interval increases in haemoglobin, haematocrit and reticulocyte count with no subsequent need for red blood cell transfusions.
Subject(s)
Anemia/therapy , Immunoglobulins, Intravenous/administration & dosage , Parvoviridae Infections/drug therapy , Parvovirus B19, Human/isolation & purification , Pregnancy Complications, Infectious/diagnosis , Adult , Anemia/blood , Anemia/virology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Cordocentesis , Echocardiography , Erythrocyte Transfusion , Female , Fetal Blood/virology , Fetal Membranes, Premature Rupture/virology , Fetus/diagnostic imaging , Fetus/virology , Humans , Hydrops Fetalis/blood , Hydrops Fetalis/diagnosis , Hydrops Fetalis/therapy , Hydrops Fetalis/virology , Immunoglobulin M/blood , Immunoglobulin M/immunology , Infant, Newborn , Infant, Premature , Infectious Disease Transmission, Vertical , Male , Parvoviridae Infections/complications , Parvoviridae Infections/congenital , Parvoviridae Infections/transmission , Parvovirus B19, Human/immunology , Polyhydramnios/diagnosis , Polyhydramnios/virology , Pregnancy , Pregnancy Complications, Infectious/virology , Treatment Outcome , Ultrasonography, PrenatalABSTRACT
Infection with parvovirus B19 and cytomegalovirus (CMV) during pregnancy might lead to fetal infection, resulting in congenital abnormalities. This study aimed to investigate the frequency of IgM and IgG antibodies against parvovirus B19 and CMV in female university students in Shiraz, in Fars province, Southern Iran. In this cross-sectional study, 370 female university students were included. Blood samples were collected from each participant and tested for anti-parvovirus B19 and CMV IgG and IgM antibodies, using commercial ELISA kits. The mean age of the participants was 24 (±7)years. Out of 370 participants, 327 (88.4%) and 9 (2.4%) were positive for IgG and IgM antibodies against CMV. Moreover, 211 (57.0%) and 4 (1.1%) of the participants were respectively positive for IgG and IgM antibodies against parvovirus B19. The difference in CMV or parvovirus B19 seropositivity between different age groups was not statistically significant (P>0.05). The findings of our study showed that more than 50% of the female university students are seropositive to CMV and parvovirus B19 infections. It highlights the importance of health education and also the laboratory screening of females at childbearing age to reduce the risk of congenital infections resulting from these viral infections.
Subject(s)
Cytomegalovirus Infections/immunology , Parvovirus B19, Human/immunology , Adolescent , Adult , Cross-Sectional Studies , Cytomegalovirus Infections/blood , Cytomegalovirus Infections/diagnosis , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/analysis , Immunoglobulin G/immunology , Immunoglobulin M/analysis , Immunoglobulin M/immunology , Iran , Students , Universities , Young AdultSubject(s)
Crohn Disease/drug therapy , Erythema Infectiosum/virology , Immunosuppressive Agents/adverse effects , Infliximab/adverse effects , Myocarditis/virology , Opportunistic Infections/virology , Parvovirus B19, Human/pathogenicity , Biopsy , Crohn Disease/diagnosis , Crohn Disease/immunology , Drug Therapy, Combination , Electrocardiography , Electrophysiologic Techniques, Cardiac , Endoscopy, Gastrointestinal , Erythema Infectiosum/diagnosis , Erythema Infectiosum/immunology , Humans , Immunocompromised Host , Male , Myocarditis/diagnosis , Myocarditis/immunology , Opportunistic Infections/diagnosis , Opportunistic Infections/immunology , Parvovirus B19, Human/immunology , Predictive Value of Tests , Risk Factors , Young AdultABSTRACT
ABSTRACT: Flame figures represent a characteristic but nondiagnostic histological finding in eosinophilic dermatoses. Some bullous autoimmune diseases with a predominant eosinophilic infiltrate, such as bullous pemphigoid, pemphigoid gestationis, and pemphigus vegetans, may show them. However, it is rare to find them in predominant neutrophilic bullous dermatoses such as linear immunoglobulin A. We present a 60-year-old man with a history of chronic urticaria, which presented a bullous disease after an acute parvovirus B19 infection. The histological findings showed an exceptional linear immunoglobulin A bullous dermatosis with an eosinophilic infiltrate in the dermis forming "flame figures." The clinical and histopathological findings for this entity may be identical to those of other dermatoses. For this reason, combining these findings with direct immunofluorescence analysis is essential for correct diagnosis of this bullous disease.
Subject(s)
Eosinophils/immunology , Erythema Infectiosum/immunology , Linear IgA Bullous Dermatosis/immunology , Parvovirus B19, Human/immunology , Skin/immunology , Adrenal Cortex Hormones/therapeutic use , Anti-Allergic Agents/therapeutic use , Antibodies, Viral/blood , Eosinophils/drug effects , Eosinophils/virology , Erythema Infectiosum/diagnosis , Erythema Infectiosum/virology , Histamine Antagonists/therapeutic use , Host-Pathogen Interactions , Humans , Immunoglobulin M/blood , Linear IgA Bullous Dermatosis/drug therapy , Linear IgA Bullous Dermatosis/pathology , Linear IgA Bullous Dermatosis/virology , Male , Middle Aged , Parvovirus B19, Human/pathogenicity , Skin/drug effects , Skin/pathology , Skin/virology , Treatment OutcomeABSTRACT
Immunoglobulin G (IgG) antibodies are crucial for protection against invading pathogens. A highly conserved N-linked glycan within the IgG-Fc tail, which is essential for IgG function, shows variable composition in humans. Afucosylated IgG variants are already used in anticancer therapeutic antibodies for their increased activity through Fc receptors (FcγRIIIa). Here, we report that afucosylated IgG (approximately 6% of total IgG in humans) are specifically formed against enveloped viruses but generally not against other antigens. This mediates stronger FcγRIIIa responses but also amplifies brewing cytokine storms and immune-mediated pathologies. Critically ill COVID-19 patients, but not those with mild symptoms, had high concentrations of afucosylated IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplifying proinflammatory cytokine release and acute phase responses. Thus, antibody glycosylation plays a critical role in immune responses to enveloped viruses, including COVID-19.